(CercleFinance.com) – Nanobiotix announces the expiration of the waiting period provided for by the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 for the global licensing, co-development and commercialization agreement with Janssen for its product-candidate NBTXR3.
‘Following the expiry of this waiting period, the license agreement becomes effective and Nanobiotix is, as such, eligible for the payment of the upfront of 30 million dollars’, recalls the biotechnology company.
As a reminder, NBTXR3 is currently being evaluated for various solid tumor indications. The license agreement with Janssen covers all worldwide territories, except those already covered by the license agreement with LianBio.